Zobrazeno 1 - 10
of 404
pro vyhledávání: '"Tim F Greten"'
Publikováno v:
Hepatic Oncology, Vol 11, Iss 1 (2024)
Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival in an aggr
Externí odkaz:
https://doaj.org/article/ce4e29d5d5194d68bc221087718359e8
Autor:
Tim F Greten, Cecilia Monge, Seth M Steinberg, William Douglas Figg, David Kleiner, Changqing Xie, Yuta Myojin, Donna Mabry Hrones, Bradford J Wood, Elliot B Levy, Bernadette Redd, Kelley Coffman-D'Annibale
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Microsatellite stable colorectal liver metastases (MSS CLM) maintain an immunosuppressive tumor microenvironment (TME). Historically, immune-based approaches have been ineffective. VB-111 (ofranergene obadenovec) is a genetically-modified
Externí odkaz:
https://doaj.org/article/70864c2e0a86452f9741c26bd58a66c8
Autor:
David E Kleiner, Tim F Greten, Cecilia Monge, Seth M Steinberg, Changqing Xie, Yuta Myojin, Kelley Coffman, Bradford J Wood, Bernadette Redd, Donna M Hrones, Elliott B Levy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/b82a12bf11294d4aaeea198c2b7d15c9
Autor:
Patrick Huang, Chi Ma, Tim F Greten, Firouzeh Korangy, Benjamin Ruf, William Telford, Mohamed-Reda Benmebarek, Cihan Oguz, Yuta Myojin, Matthias Seifert, Justin Lack, Kylynda Bauer, Marina Villamor Paya
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/36166d818bed4c0ea8f1b8a8241f0a7a
Autor:
Chi Ma, Tim F Greten, Firouzeh Korangy, Benjamin L Green, Benjamin Ruf, Mohamed-Reda Benmebarek, Yuta Myojin, Jonathan Qi, Simon Wabitsch, Amran Nur, Kylynda C Bauer, Rajiv Trehan, Danielle Springer, Audrey Noguchi, Morteza Peiravi, Heather Potts
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/6d696f0757554567bc25be120834fb8e
Autor:
Stephen M Hewitt, David E Kleiner, Tim F Greten, William D Figg, Cecilia Monge, Seth M Steinberg, Maggie Cam, Benjamin Ruf, Austin G Duffy, Jonathan M Hernandez, Changqing Xie, Yuta Myojin, Kelley Coffman, Donna Mabry Hrones, Sophie Wang, Bradford J Wood, Elliot B Levy, Israa Juburi, Bernadette Redd, Philip Homan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of pexastimogene devacirepvec (PexaVec) plus durvalumab (anti-programmed death liga
Externí odkaz:
https://doaj.org/article/7d02b8ba4ef24ff8856cf44022b698f1
Autor:
James L Gulley, James Larkin, Leisha A Emens, Mario Sznol, Madhav Dhodapkar, Daniel S Chen, Roy S Herbst, Tim F Greten, Robert L Ferris, Luca Mazzarella, Paolo A Ascierto, Marc S Ernstoff, Michael B Atkins, Kim A Margolin, Brian I Rini, Michael R Bishop, Suresh S Ramalingam, Meredith M Regan, Rachel W Humphrey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
The broad activity of agents blocking the programmed cell death protein 1 and its ligand (the PD-(L)1 axis) revolutionized oncology, offering long-term benefit to patients and even curative responses for tumors that were once associated with dismal p
Externí odkaz:
https://doaj.org/article/924c88f5ec8f4838a91c8255c8c43862
Autor:
Amaia Lujambio, Thomas Yau, Lipika Goyal, Andrew X Zhu, Ignacio Melero, Tim F Greten, Ann-Lii Cheng, Bruno Sangro, David J Pinato, Peter R Galle, Ghassan K Abou-Alfa, Austin G Duffy, Anthony B. El-Khoueiry, Richard S Finn, Aiwu Ruth He, Ahmed O Kaseb, Robin Kate Kelley, Riccardo Lencioni, Donna Mabry Hrones, Roberto I Troisi, Andrea Wilson Woods
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC ha
Externí odkaz:
https://doaj.org/article/c395a80c692945e793e9d243958829ae
Publikováno v:
Hepatic Oncology, Vol 5, Iss 1 (2018)
Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HC
Externí odkaz:
https://doaj.org/article/8218a6d9bcb34f1e8a0e05323e9241fc
Autor:
Tobias Eggert, José Medina-Echeverz, Tamar Kapanadze, Michael J Kruhlak, Firouzeh Korangy, Tim F Greten
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e112717 (2014)
Subcutaneous tumors induce the accumulation of myeloid derived suppressor cells (MDSC) not only in blood and spleens, but also in livers of these animals. Unexpectedly, we observed a moderate increase in serum transaminases in mice with EL4 subcutane
Externí odkaz:
https://doaj.org/article/312c76e60e354aac9e679f90dadc4bd0